About Zymedi
Zymedi is a Healthcare company based in Incheon (South Korea) founded in 2019. Therapeutics for multiple diseases are developed using Aminoacyl-tRNA Synthetase technology. Zymedi has raised $29.54 million across 2 funding rounds from investors including Industrial Bank of Korea, Company K Partners and UTC Investment. Its chief executive, as recorded, is Nam Hoon Kwon. Zymedi offers products and services including ZMA001, ZMP201, ZMC003, and ARS Platform. Its focus areas include Life Sciences, Oncology, Drugs and Colorectal Cancer.
Company details
Zymedi was founded in 2019 and is based in Incheon, South Korea. Operations focus on the biotechnology sector, where therapeutics for various diseases are developed. Aminoacyl-tRNA Synthetase-based drugs form the core pipeline, including ZM-A001 targeted at pulmonary arterial hypertension, ZM-C001 for non-alcoholic steatohepatitis, and ZM-C101 for colorectal cancer. Leadership is provided by CEO Nam Hoon Kwon.
- Headquarters Incheon, South Korea
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zymedi.com
- Social LinkedIn
- Total Equity Funding$29.54M (USD)
in 2 rounds
- Latest Funding Round$12.08M (USD), Series A
May 2023
- InvestorsIndustrial Bank of Korea
& 6 more
Products & Services of Zymedi
Zymedi offers a comprehensive portfolio of products and services, including ZMA001, ZMP201, ZMC003, and ARS Platform.
Targets pulmonary arterial hypertension for precision medicine applications.
Vaccine candidate for immune-related disorders treatment.
Drug for neurological diseases addressing unmet needs.
Enables development of first-in-class drugs for hard-to-treat conditions.
Funding Insights of Zymedi
Zymedi has successfully raised a total of $29.54M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.08 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.54M
- Total Rounds 2
- Last Round Series A — $12.08M
- First Round $17.46M
(Jun 2021)
- Investors Count 7
All 2 funding rounds of Zymedi with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $12.08M | Series A | – | Company K Partners, UTC Investment | – |
| Jun 2021 | $17.46M | Series A | – | – | – |
7 investors in total: 7 institutional.
Investors in Zymedi
Zymedi has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Industrial Bank of Korea, Company K Partners and UTC Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
Venture capital and private equity investment firm | utc.co.kr | Seoul, South Korea | ||
Venture capital investments are managed to support startup ecosystems. | kvic.or.kr | Seoul, South Korea | ||
| medytoxventure.com | ||||
Industrial bank | 1961 | ibk.co.kr | Seoul, South Korea | |
| ckdpartners.tcc.mode | ||||
| atium.tcc.mode |
Investor details for Zymedi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zymedi
1 people are tracked at Zymedi (1 in leadership).
| Name | Role | Group |
|---|---|---|
Nam Hoon Kwon | CEO | Leadership |
Complete people profiles for Zymedi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zymedi
3 dated milestones of Zymedi across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Zymedi is founded.
- Funding First funding round of $17.5M.
- Funding Latest funding round, Series A, of $12.1M.
Web traffic of Zymedi
The website of Zymedi (zymedi.com) receives about 4K visits a month.
- Monthly visits4K
▼ 2.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zymedi
Complete news archive for Zymedi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zymedi
Zymedi was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Zymedi is headquartered in Incheon, South Korea.
Nam Hoon Kwon is the CEO of Zymedi, as recorded in our data.
Zymedi is a funded company, having raised a total of $29.54M across 2 funding rounds to date. The company's 1st funding round was a Series A of $17.46M, raised on Jun 2021.
Zymedi was founded in 2019 and is based in Incheon, South Korea. Operations focus on the biotechnology sector, where therapeutics for various diseases are developed. Aminoacyl-tRNA Synthetase-based drugs form the core pipeline, including ZM-A001 targeted at pulmonary arterial hypertension, ZM-C001 for non-alcoholic steatohepatitis, and ZM-C101 for colorectal cancer. Leadership is provided by CEO Nam Hoon Kwon.
Zymedi offers ZMA001, ZMP201, ZMC003, and ARS Platform.
Zymedi has 7 investors. Key investors include Industrial Bank of Korea, Company K Partners, UTC Investment, Korea Venture Investment Corp, and Medytox Venture.